Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDIO Cardio Diagnostics	$3.64 +4.0%	$3.94	$3.22 ▼ $53.10	$6.41M	2.96	62,255 shs	4,513 shs
NNVC NanoViricides	$1.37	$1.50	$0.94 ▼ $2.07	$22.02M	0.96	242,857 shs	37,947 shs
QTTB Q32 Bio	$1.88 +1.4%	$1.88	$1.35 ▼ $53.79	$22.88M	N/A	642,062 shs	52,038 shs
RLYB Rallybio	$0.59 -2.0%	$0.44	$0.22 ▼ $1.25	$24.82M	-1.12	1.21 million shs	221,629 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDIO Cardio Diagnostics	-3.58%	-8.38%	-19.91%	-17.45%	-74.07%
NNVC NanoViricides	-4.86%	-8.67%	-18.93%	-7.43%	-25.14%
QTTB Q32 Bio	+2.21%	+2.21%	-15.14%	+12.12%	-95.28%
RLYB Rallybio	+6.56%	+13.24%	+31.15%	+83.73%	-45.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDIO Cardio Diagnostics	2.6369 of 5 stars	3.5	3.0	1.9	1.7	0.6
NNVC NanoViricides	0.752 of 5 stars	0.0	5.0	2.5	0.0	0.0
QTTB Q32 Bio	2.5931 of 5 stars	3.1	4.0	1.9	1.7	0.6
RLYB Rallybio	3.1923 of 5 stars	3.0	4.0	3.3	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDIO Cardio Diagnostics	3.00	Buy	$60.00	1,526.02% Upside
NNVC NanoViricides	0.00	N/A	N/A	N/A
QTTB Q32 Bio	2.25	Hold	$12.17	548.89% Upside
RLYB Rallybio	2.00	Hold	$10.00	1,583.50% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDIO Cardio Diagnostics	$40K	162.36	N/A	N/A	$5.52 per share	0.67
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A
QTTB Q32 Bio	$1.16M	19.72	N/A	N/A	($1.00) per share	-1.88
RLYB Rallybio	$640K	38.79	N/A	N/A	$1.10 per share	0.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDIO Cardio Diagnostics	-$8.38M	N/A	0.00	∞	N/A	-30,465.10%	-72.78%	-66.17%	N/A
NNVC NanoViricides	-$8.29M	-$0.70	N/A	∞	N/A	N/A	-87.90%	-78.69%	N/A
QTTB Q32 Bio	-$47.73M	-$4.30	N/A	N/A	N/A	N/A	-2,709.70%	-61.16%	11/6/2025 (Estimated)
RLYB Rallybio	-$57.78M	-$0.94	N/A	N/A	N/A	-5,473.33%	-71.66%	-65.06%	11/6/2025 (Estimated)

Latest CDIO, RLYB, NNVC, and QTTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CDIO Cardio Diagnostics	-$1.80	-$0.97	+$0.83	-$0.97	$0.08 million	$0.01 million
8/7/2025	Q2 2025	RLYB Rallybio	-$0.2450	-$0.22	+$0.0250	-$0.22	N/A	$0.21 million
8/6/2025	Q2 2025	QTTB Q32 Bio	-$1.14	-$0.78	+$0.36	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDIO Cardio Diagnostics	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDIO Cardio Diagnostics	N/A	23.52	19.47
NNVC NanoViricides	N/A	3.44	2.47
QTTB Q32 Bio	1.68	5.06	5.06
RLYB Rallybio	N/A	9.98	9.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDIO Cardio Diagnostics	8.06%
NNVC NanoViricides	10.30%
QTTB Q32 Bio	31.32%
RLYB Rallybio	90.34%

Insider Ownership

Company	Insider Ownership
CDIO Cardio Diagnostics	22.30%
NNVC NanoViricides	4.60%
QTTB Q32 Bio	40.00%
RLYB Rallybio	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDIO Cardio Diagnostics	1	1.76 million	1.37 million	Not Optionable
NNVC NanoViricides	20	16.07 million	14.92 million	Optionable
QTTB Q32 Bio	39	12.20 million	7.32 million	N/A
RLYB Rallybio	40	41.79 million	38.15 million	Not Optionable

CDIO, RLYB, NNVC, and QTTB Headlines

Recent News About These Companies

Rallybio Corporation (NASDAQ:RLYB) Short Interest Down 31.8% in July

August 20 at 2:15 AM | americanbankingnews.com

TD Cowen Reaffirms Their Buy Rating on Rallybio (RLYB)

August 12, 2025 | theglobeandmail.com

Rallybio First Half 2025 Earnings: US$0.43 loss per share (vs US$0.83 loss in 1H 2024)

August 9, 2025 | finance.yahoo.com

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 8, 2025 | finance.yahoo.com

Evercore ISI Remains a Hold on Rallybio (RLYB)

July 16, 2025 | theglobeandmail.com

RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia ... - Nasdaq

July 11, 2025 | nasdaq.com

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - Morningstar

July 9, 2025 | morningstar.comM

Here's Why Shares in Recursion Pharmaceuticals Surged Today

July 8, 2025 | finance.yahoo.com

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

July 8, 2025 | finance.yahoo.com

Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug

July 8, 2025 | msn.com

Rallybio Sells REV102 Program to Recursion Pharmaceuticals

July 8, 2025 | tipranks.com

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

June 13, 2025 | finance.yahoo.com

Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook

May 24, 2025 | investing.com

Rallybio shareholders elect directors, ratify auditor

May 18, 2025 | uk.investing.com

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finance.yahoo.com

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

April 29, 2025 | finance.yahoo.com

Jones Trading Downgrades Rallybio (RLYB)

April 15, 2025 | msn.com

Rallybio downgraded to Hold from Buy at JonesResearch

April 14, 2025 | markets.businessinsider.com

Rallybio downgraded to In Line from Outperform at Evercore ISI

April 11, 2025 | markets.businessinsider.com

Rallybio (RLYB) was downgraded to a Hold Rating at H.C. Wainwright

April 10, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO, RLYB, NNVC, and QTTB Company Descriptions

Cardio Diagnostics NASDAQ:CDIO

$3.64 +0.14 (+4.00%)

Closing price 03:59 PM Eastern

Extended Trading

$3.68 +0.03 (+0.96%)

As of 04:57 PM Eastern

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

NanoViricides NYSE:NNVC

$1.37 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.38 +0.01 (+0.73%)

As of 06:58 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Q32 Bio NASDAQ:QTTB

$1.88 +0.03 (+1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$1.86 -0.01 (-0.80%)

As of 05:32 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Rallybio NASDAQ:RLYB

$0.59 -0.01 (-2.03%)

Closing price 04:00 PM Eastern

Extended Trading

$0.59 0.00 (-0.51%)

As of 06:51 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time